Richard A. Heyman
CIK 1584759 · last filed 2026-07-28
Richard A. Heyman is a corporate insider who has filed 92 SEC Form 4 insider transactions across 9 companies since 2013. The most recent filing, for ELVN, was dated Sep 4, 2026. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.04M
9
92
-$1.74M
Filer Profile
DEL MAR, CA 92014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ORIC | Director | 251,972 | $12.04 | $3.03M | -$524.4K | 20 | 2026-07-28 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 149,218 | $14.59 | $2.18M | -$1.09M | 25 | 2026-02-19 |
| PMVP | Director | 975 | $1.40 | $1.4K | -$126.9K | 8 | 2025-06-09 |
| RayzeBio, Inc. (RYZB) Delisted | Director | 0 | $62.49 | $0 | $0 | 1 | 2024-02-27 |
| Metacrine, Inc. (MTCR) Delisted | Director | — | $0.49 | — | $0 | 2 | 2022-09-06 |
| Gritstone bio, Inc. (GRTS) Delisted | Director | — | $0.03 | — | $0 | 4 | 2022-06-22 |
| KINETA, INC./DE (YMTX) Delisted | Director | 1,160 | $13.23 | $15.3K | $0 | 3 | 2021-06-04 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 3 | 2015-08-27 |
| VivoSim Labs, INC. (ONVO) Delisted | Director | — | $2.04 | — | $0 | 3 | 2015-08-24 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-04 | ELVN | Notice (144) | −38,000 | -$2.25M | EDGAR |
| 2026-07-28 | ORIC | Mixed | −9,600 | -$151.9K | EDGAR |
| 2026-07-08 | ORIC | Sell (S) | −300 | -$3.6K | EDGAR |
| 2026-07-06 | ORIC | Notice (144) | −7,000 | -$84.0K | EDGAR |
| 2026-07-06 | ORIC | Notice (144) | −6,400 | -$76.8K | EDGAR |
| 2026-02-19 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,230 | -$32.2K | EDGAR |
| 2026-02-17 | ELVN | Notice (144) | −1,230 | -$32.9K | EDGAR |
| 2026-02-17 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-01-22 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,230 | -$32.9K | EDGAR |
| 2026-01-20 | ELVN | Notice (144) | −1,230 | -$32.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.